2 completed, 1 no longer available. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
Follow agerafenib: new trials by email Literature Review of agerafenib trials Research Report on agerafenib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Continued Access to RXDX-105 RXDX-105 - Non Small Cell Lung Cancer, Ovarian Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 3 | 2018-12-14 | 2025-05-15 |
| Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors RXDX-105 - Solid Tumors | Phase 1 | Completed | Hoffmann-La Roche | 143 | 2013-06-01 | 2019-04-25 |
| Expanded Access to RXDX-105 for Cancers With RET Alterations RXDX-105 - Cancers With RET Alterations | No longer available | Hoffmann-La Roche | 2019-04-26 |
Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Ovarian Neoplasms (1)
Hoffmann-La Roche (2) · Memorial Sloan Kettering Cancer Center (1)
United States (3)